Compare · ORKA vs QUIT
ORKA vs QUIT
Side-by-side comparison of Oruka Therapeutics Inc. (ORKA) and Achieve Life Sciences Inc. (QUIT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ORKA and QUIT operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $6.73B, about 10.1x QUIT ($666.8M).
- ORKA has been more active in the news (12 items in the past 4 weeks vs 1 for QUIT).
- ORKA has more recent analyst coverage (11 ratings vs 0 for QUIT).
- Company
- Oruka Therapeutics Inc.
- Achieve Life Sciences Inc.
- Price
- -
- -
- Market cap
- $6.73B
- $666.8M
- 1M return
- +37.72%
- -
- 1Y return
- +251.20%
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 12
- 1
- Recent ratings
- 11
- 0
QUIT
Achieve Life Sciences Inc.
AchieveRx, The Quit Company (Nasdaq: ACHV; QUIT effective November 10, 2026 ; formerly doing business as Achieve Life Sciences, Inc. ) is a late-stage pharmaceutical company with a singular focus on nicotine dependence. AchieveRx's mission is to develop medicine for people who want to quit smoking or vaping. That medicine is cytisinicline, an investigational compound. Three ideas guide the Company: simplicity, science, and second chances, for good.
Latest ORKA
- Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $706,700 worth of shares (7,000 units at $100.96) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Oruka Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Oruka Therapeutics Inc.
- Senior Vice President, Finance Agarwal Arjun exercised 10,000 shares at a strike of $15.69 and sold $1,049,658 worth of shares (10,000 units at $104.97) as part of a pre-agreed trading plan (SEC Form 4)
- Director Ball Kristine M exercised 18,000 shares at a strike of $6.84 and sold $1,888,749 worth of shares (18,000 units at $104.93) as part of a pre-agreed trading plan (SEC Form 4)
- Oruka Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form 10-Q filed by Oruka Therapeutics Inc.
- Oruka Therapeutics to Participate in Multiple Upcoming Conferences
- Chief Executive Officer Klein Lawrence Otto exercised 25,000 shares at a strike of $7.80 and sold $2,390,125 worth of shares (25,000 units at $95.60) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 8-K filed by Oruka Therapeutics Inc.